OncLive SOSS

Most Recent

Shaping a New Future With Novel Therapeutics in Gynecologic Cancers

October 31st 2020

By Brittany Cote

Ritu Salani, MD, MBA, discusses updates to PARP inhibition and FRα-targeting agents in ovarian cancer, the role of bevacizumab across all lines of ovarian cancer therapy, and immunotherapy highlights in cervical and endometrial cancer.

Frontline Maintenance Therapy Transforms Advanced Ovarian Cancer With PARP Inhibitors

October 30th 2020

By Erica DiNapoli

Mae Zakhour, MD, discusses the rise of PARP inhibitors as frontline maintenance therapy in advanced ovarian cancer and the key data that supported these regulatory decisions.

FDA Approves First Companion Diagnostic for Expanded EGFR TKIs in NSCLC

October 30th 2020

By Kristi Rosa

The FDA has approved the cobas EGFR Mutation Test v2 as a companion diagnostic for EGFR TKIs in the treatment of patients with EGFR-mutated non–small cell lung cancer.

Tan Speaks to Benefits of Fixed-Dose Pertuzumab/Trastuzumab Combo in HER2+ Breast Cancer

October 30th 2020

By Erica DiNapoli

Antoinette R. Tan, MD, discusses the FDA approval of the fixed-dose combination of SC pertuzumab and trastuzumab with hyaluronidase, in combination with IV chemotherapy in HER2-positive breast cancer.

Atezolizumab Plus Bevacizumab Approved in China for Hepatocellular Carcinoma

October 30th 2020

By Kristi Rosa

The China National Medical Products Administration has approved the combination of atezolizumab plus bevacizumab for use in patients with unresectable hepatocellular carcinoma who have not received previous systemic therapy.

Latest Videos

Dr. Tap on the Rise of Precision Medicine in Sarcoma
Dr. Tap on the Rise of Precision Medicine in Sarcoma
Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape
Hepatocellular Carcinoma: A Rapidly Evolving Treatment Landscape
Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC
Dr. Azad on Selecting Between Regorafenib and TAS-102 in CRC
Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC
Considerations of Adjuvant Therapy in EGFR+ ES-NSCLC
Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients
Back to the Future: How New and Emerging Trends in CAR T-Cell Therapy Can Affect Your Patients
Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma
Dr. D’Amato on the Importance of Multidisciplinary Care in Sarcoma
Rapids Readouts: Phase 3 CheckMate 238 Trial
Rapids Readouts: Phase 3 CheckMate 238 Trial
Dr. Ahn on the Identification of NTRK Alterations in CRC
Dr. Ahn on the Identification of NTRK Alterations in CRC
Dr. Atkins on the Expanding Role of Immunotherapy in Oncology
Dr. Atkins on the Expanding Role of Immunotherapy in Oncology
Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma
Dr. Tap on the Importance of Community and Academic Collaboration in Sarcoma
Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC
Dr. Spira on the Rationale of the CHRYSALIS Trial in EGFR-Mutant NSCLC
Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer
Dr. Cohen on the Design on the SPEARHEAD-2 Trial in Head and Neck Cancer
Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC
Dr. Shore on the Need for Further Education on Molecular Testing in mCRPC
Dr. Wolin on the Treatment Landscape of NETs
Dr. Wolin on the Treatment Landscape of NETs
Dr. Goff on the Need to Identify Novel Targets in HCC
Dr. Goff on the Need to Identify Novel Targets in HCC
Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer
Dr. Pant on the Role of Genetic Testing in Pancreatic Cancer
Dr. Azad on Third-Line Treatment Options in CRC
Dr. Azad on Third-Line Treatment Options in CRC
Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC
Dr. Henske on the Potential Role of Glutathione in Chromophobe RCC
Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC
Dr. Hammers on Investigational Strategies to Inflame Tumors in RCC
Dr. Luke on the Importance of BRAF in Melanoma
Dr. Luke on the Importance of BRAF in Melanoma
Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma
Dr. Weber on Results of the COMBI-AD Trial in Stage III BRAF-Mutant Melanoma
Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC
Dr. Levy on the Mechanism of Action of Telaglenastat in NSCLC
Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer
Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer

Featured Content

All Content

Chemoimmunotherapy Combos “Game-Changing” in Frontline Metastatic NSCLC

October 30th 2020

By Brittany Cote

Nicholas Rohs, MD, discusses the progress made with chemoimmunotherapy combinations in frontline non–small cell lung cancer, future research directions, and emerging approaches that seek to propel progress in this disease.

ESMO 2020 Highlights With Cora Sternberg, MD, FACP

October 30th 2020

By Cora Sternberg, MD, FACP, Weill Cornell Medicine

TROPHY U-01 cohort 1 is a phase 2 open-label study of sacituzumab govitecan in patients with metastatic urothelial cancer and disease progression after both platinum-based regimens and checkpoint inhibitors.

High Response Rates Heighten Excitement With CAR T-Cell Therapy in Multiple Myeloma

October 30th 2020

By Jessica Hergert

Faiz Anwer, MD, discusses the growing role of CAR T-cell therapy in multiple myeloma and areas of unmet need.

Niraparib Approved in Europe for Frontline Maintenance in Advanced Ovarian Cancer

October 29th 2020

By Kristi Rosa

The European Commission has approved niraparib for use as a frontline monotherapy maintenance option in adult patients with advanced epithelial, high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response after platinum-based chemotherapy.

Raez on the Rise of Liquid Biopsy in Lung Cancer

October 29th 2020

By OncLive Staff

In our exclusive interview, Dr. Raez provides insight into the advantages and disadvantages of liquid biopsy relative to tissue biopsy and forecasts the utility of liquid biopsy within the field of lung cancer as more of these assays become available.

FDA Grants Priority Review to Cemiplimab for Advanced NSCLC With High PD-L1 Expression

October 29th 2020

By Kristi Rosa

The FDA has granted a priority review designation to a supplemental biologics license application for cemiplimab-rwlc for the frontline treatment of patients with locally advanced or metastatic non–small cell lung cancer with a PD-L1 expression of 50% or greater.

Future of Immunotherapy in Melanoma to Focus on Overcoming Resistance, Personalizing Regimens

October 29th 2020

By Gina Mauro

With an estimated 5-year survival rate of 50% and an ongoing issue of resistance, next steps with immunotherapy in melanoma will focus on stratifying patients, personalizing therapy, and refining localized regimens.

Standardizing Optimal Diagnostic Procedures and Monitoring Strategies in CML

October 29th 2020

By Jessica Hergert

During the 2020 Institutional Perspectives in Cancer webinar on hematologic malignancies, Sudipto Mukherjee, MD, PhD, MPH, provides detail as to some of these nuances and the optimal management of patients with CML.

Novel Triplets May Overcome Resistance to Targeted Therapy in BRAF+ Melanoma

October 29th 2020

By Kristi Rosa

The addition of anti–PD-1/PD-L1 to combination BRAF and MEK inhibition has been shown to improve progression-free survival and duration of response in patients with BRAF-mutated melanoma, suggesting potential to overcome resistance to targeted approaches.

Deeper Understanding of Disease Biology Needed in Melanoma to Move the Needle Forward

October 29th 2020

By Erica DiNapoli

Jason J. Luke, MD, discusses the recent advancements with BRAF-targeted therapies and PD-1 checkpoint inhibitors in melanoma.

x